Clinical Trial Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
| NCT ID | NCT03839771 |
| Title | A Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy, Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive Chemotherapy (HOVON150AML) |
| Acronym | HOVON150AML |
| Recruitment | Recruiting |
| Gender | both |
| Phase | Phase III |
| Variant Requirements | Yes |
| Sponsors | Stichting Hemato-Oncologie voor Volwassenen Nederland |
| Indications | |
| Therapies | |
| Age Groups: | adult | senior |
| Covered Countries | NLD | FRA | ESP | DEU | BEL | AUT | AUS |
CKB BOOST